Healthcare Stock Comparisons
New Stock Analyses Compare Valuation and Risk Across Five Healthcare Companies
Anonymous
Key Points
1
Aprea Therapeutics had a beta of 1.54, making it 54% more volatile than the S&P 500, while Alkermes had a beta of 0.31, making it 69% less volatile than the index.
2
Corcept Therapeutics had substantially higher insider ownership than ANI Pharmaceuticals: insiders held 20.7% of Corcept shares, compared with 8.1% of ANI shares; institutional ownership was 93.6% and 76.0%, respectively.
3
Anika Therapeutics had a beta of 0.20, compared with Entera Bio’s 1.38, meaning Anika’s stock was described as 80% less volatile than the S&P 500 while Entera’s was 38% more volatile.
4
In the comparison with Lyell Immunopharma, Anika Therapeutics had 91.5% institutional ownership and 12.1% insider ownership, versus 66.0% and 6.2%, respectively, for Lyell; Anika was also said to prevail on nine of 14 factors.
5
Vivos Therapeutics had a beta of 6.04—504% more volatile than the S&P 500—while Establishment Labs had a beta of 1.05; the comparison also found Establishment Labs ahead on 10 of 14 factors.
Healthcare stocks face intense scrutiny as investors compare small and mid-cap companies across valuations, profitability, and risk. Watchlist News analyzed multiple head-to-head matchups, revealing stark differences in volatility, institutional backing, and growth potential. Alkermes dominated Aprea Therapeutics on 11 of 15 factors, while riskier plays like Vivos Therapeutics offered higher upside—but at extreme cost.
Alkermes Crushes Aprea on Stability and Ownership
Alkermes outperformed Aprea Therapeutics in nearly every measure except valuation and analyst upside. Watchlist News found Alkermes had stronger revenue, better earnings, and far greater institutional ownership. The real standout: Alkermes carried a beta of 0.31—making it 69% less volatile than the S&P 500. Aprea's beta hit 1.54, meaning it swung 54% more wildly than the broader market. For risk-averse investors, Alkermes was the safer bet.
ANI Offers Better Value Than Corcept Despite Weak Insiders
ANI Pharmaceuticals looked cheaper and promised more growth upside than Corcept Therapeutics, though Corcept boasted stronger earnings and deeper insider ties. Corcept's insiders controlled 20.7% of shares versus ANI's 8.1%, according to Watchlist News. Institutional ownership also favored Corcept at 93.6% to ANI's 76.0%. The tradeoff: ANI's lower price tag appealed to value hunters willing to trade insider confidence for potential returns.
Anika Dominates Two Rivals Despite Lower Upside Targets
Anika Therapeutics won on nine of 14 factors against Lyell Immunopharma and beat Entera Bio across revenue, earnings, and valuation. Watchlist News noted Anika's extreme stability: a 0.20 beta meant its stock moved 80% less than the S&P 500. Entera Bio's 1.38 beta made it 38% more volatile. Anika also held 91.5% institutional ownership and 12.1% insider stakes—both ahead of Lyell's 66.0% and 6.2%. Analysts, however, predicted bigger price jumps for the riskier competitors.
Vivos Offers Wild Swings for Desperate Momentum Traders
Vivos Therapeutics carried massive upside potential but came with punishing volatility. Watchlist News reported Vivos had a beta of 6.04—meaning it swung 504% more violently than the S&P 500. By contrast, competitor Establishment Labs posted a 1.05 beta and beat Vivos on 10 of 14 factors. Establishment Labs also showed far lower risk. Vivos, however, attracted traders hunting explosive gains willing to stomach stomach-churning price swings and weak institutional ownership of just a fraction of shares.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
17
Articles
16
Reach
33
A
AnonymousAuthor
